Transcatheter Aortic Valve Replacement for Patients at Low Surgical Risk—Selective or Ubiquitous?

Transcatheter aortic valve replacement (TAVR) for aortic stenosis (AS) was approved by the US Food and Drug Administration (FDA) on August 16, 2019, for patients at low surgical risk. It is estimated that this risk group constitutes approximately 80% of patients currently undergoing surgical aortic valve replacement (SAVR) in the United States.¹ The rational dissemination of TAVR to patients at low surgical risk and younger patients poses critical challenges to multiple stakeholders.